The next generation of drugs will target specific conditions associated with diabetes and obesity, such as sleep apnoea, fatty liver disease, chronic kidney disease and heart disease, he adds
Evidence for glutathione use in fatty liver disease remains limited, with small-scale studies showing mixed results and no large clinical trials establishing clear benefits
NASH Treatment: The ESSENCE trial shows that 37.0% of people treated with semaglutide 2.4 mg achieved improvement in liver fibrosis with no worsening of steatohepatitis compared to 22.5% on placebo
Yabe, T
If its been left at room temperature for too long, it may not be effective anymore
Clinical trial data on Retatrutides benefits is striking: Weight loss up to 24% of total body weight within 48 weeks outpacing both semaglutide and tirzepatide in head-to-head comparisons 3050% reduction in appetite , making dietary adherence significantly easier Visceral fat reduction of up to 40%, targeting the most metabolically harmful fat stored around organs Improved glycemic control and reduced insulin resistance, with benefits for those at risk of or managing type 2 diabetes Liver health improvement emerging data suggests positive effects on non-alcoholic fatty liver disease (NAFLD) Elevated resting energy expenditure , meaning your body burns more calories at rest For residents of Dubai pursuing sustainable, medically supervised weight management, these outcomes represent a meaningful leap forward